vTv Therapeutics Inc.

AI Score

0

Unlock

13.34
-0.29 (-2.13%)
At close: Jan 14, 2025, 2:45 PM
12.90
-3.30%
Pre-market Jan 15, 2025, 06:00 AM EST
undefined%
Bid 11.31
Market Cap 34.85M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -4.37
PE Ratio (ttm) -3.05
Forward PE n/a
Analyst Buy
Ask 21.82
Volume 24,682
Avg. Volume (20D) 30,273
Open 13.46
Previous Close 13.63
Day's Range 13.20 - 13.63
52-Week Range 7.38 - 30.99
Beta undefined

About VTVT

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is a...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2015
Employees 16
Stock Exchange NASDAQ
Ticker Symbol VTVT

Analyst Forecast

According to 1 analyst ratings, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 162.37% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
5 months ago · Source
-24.53%
vTv Therapeutics shares are trading lower after th... Unlock content with Pro Subscription
5 months ago · Source
+0.9%
vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.